Surgical Trial In Traumatic intraCerebral Haemorrhage (STITCH): a randomised controlled trial of Early Surgery compared with Initial Conservative Treatment

Barbara A Gregson,1* Elise N Rowan,1 Richard Francis,1 Paul McNamee,2 Dwayne Boyers,2 Patrick Mitchell,1 Elaine McColl,3 Iain R Chambers,4 Andreas Unterberg5 and A David Mendelow1 on behalf of the STITCH(TRAUMA) investigators

1Neurosurgical Trials Group, Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK
2Health Economics Research Unit, University of Aberdeen, Aberdeen, UK
3Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK
4South Tees Hospitals Foundation Trust, James Cook University Hospital, Middlesbrough, UK
5Department of Neurosurgery, University of Heidelberg, D-69120 Heidelberg, Germany

*Corresponding author

Declared competing interests of authors: Barbara Gregson and A David Mendelow received a grant from the Medical Research Council and Efficacy and Mechanism Evaluation Programme to undertake Surgical Trial In spontaneous lobar intraCerebral Haemorrhage (STICH II). A David Mendelow also reports grants from Newcastle Neurosurgery Foundation Ltd for sponsorship of meetings outwith this study and personal fees from Stryker Ltd for consultancy work. Elaine McColl is a member of the National Institute for Health Research Journals Library Editorial Group, but had no role in editorial decisions concerning this publication. Newcastle University is reimbursed for the time devoted to editorial work.

Published September 2015
DOI: 10.3310/hta19700
Scientific summary

Surgical Trial In Traumatic intraCerebral Haemorrhage (STITCH)
Health Technology Assessment 2015; Vol. 19: No. 70
DOI: 10.3310/hta19700

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

In the UK there are 1.4 million presentations of head injury at emergency departments each year. The mortality rate for severe isolated traumatic brain injury varies between 16% and 40%. More than 150,000 of those who present to emergency departments with head injury are admitted to hospital each year. Of these, about 20,000 injuries are serious. One year after a serious head injury, 35% of patients are dead or severely disabled. Intracranial haemorrhage occurs in more than 60% of serious head injuries in one or more of three types: extradural haematoma (EDH), subdural haematoma (SDH) and intracerebral haemorrhage (ICH). Prompt surgical removal of significant SDH and EDH is of established and widely accepted value. ICH is more common and is associated with a worse outcome but the role of surgical removal of the clot remains undefined.

Surgical practice in the treatment of traumatic ICH (TICH) differs widely. Several issues inform the debate:

(a) Contused brain does not recover but appears as encephalomalacic brain tissue loss on convalescent phase imaging. This suggests that removing TICH does not increase tissue loss.
(b) Extravasated blood is believed to be neurotoxic, leading to secondary injury that may be avoided by surgical removal.
(c) Larger TICHs may be associated with an ischaemic penumbra of brain tissue that could be salvaged.
(d) Some TICHs expand to the point at which they cause mass effect with high intracranial pressure (ICP), resulting in secondary brain injury.

The aim of early surgical TICH removal is to prevent secondary brain injury from these mechanisms. Use of the operation varies around the world. It is more frequently done in the Far East than in Europe or the USA.

Traditional neurosurgical care of patients with severe head injury is frequently based on ICP measurement. Patients with high ICP (>30 mmHg) and TICH would undergo craniotomy and those with low ICP (<20 mmHg) would be managed conservatively. Patients with ICP between 20 and 30 mmHg would be observed with ongoing ICP monitoring and undergo craniotomy if the ICP rises. This ICP-based approach has been recommended by the Brain Trauma Foundation, but has recently been challenged in the Trial of Intracranial Pressure Monitoring in Traumatic Brain Injury (BEST TRIP) from Latin America. In the light of this controversy, the early management of patients with TICH needs evaluation to determine if Early Surgery should become part of the standard of care in the same way it is for significant EDH and SDH.

There have been trials of surgery for spontaneous intracerebral haemorrhage (SICH) but none so far of surgery for TICH. The Cochrane Review (2nd edition) has shown benefit from surgical evacuation for SICH (Prasad K, Mendelow AD, Gregson B. Surgery for primary supratentorial intracerebral haemorrhage. Cochrane Database Syst Rev 2008;4:CD000200). There are differences in the pathogenesis, clinical behaviour and outcome of the two conditions (SICH and TICH). Patients suffering a TICH tend to be younger and, therefore, their level of disability may have a larger effect on their ability to return to work and their economic output. TICHs are more likely to be lobar, to be superficial and to have a medium-sized volume (25–65 cc). These differences between the conditions mean that we cannot derive the role of surgery for TICH from SICH trials.

We already know that surgery is effective in patients with traumatic EDH and SDH and that Early Surgery results in improved outcomes compared with delayed surgery. This is not known for TICH. If Early Surgery is of benefit to these patients, then implementation of early referral and diagnosis with immediate treatment may reduce death and disability in this specific group of head-injured patients.
Several authors have compared surgery with conservative treatment in single-centre retrospective series and recommended surgery for larger TICHs even if patients were in an apparently good clinical state initially. None of these studies involved randomisation into surgical and non-surgical groups. They also differed in the characteristics of the parenchymal blood. Such uncontrolled observational studies may be potentially misleading and a randomised controlled trial was needed.

Guidelines for the surgical management of traumatic brain injury were published in 2006 in *Neurosurgery* (Bullock M, Chesnut R, Ghajar J, Gordon D, Hartl R, Newell D, et al. Surgical management of traumatic parenchymal lesions. *Neurosurgery* 2006;58:S25–46; discussion Si–iv). These confirmed that studies in this area have been observational and that there is a lack of evidence from well-designed randomised controlled trials. Those studies that attempt to compare outcome between surgical and non-surgical groups cannot adequately control for unknown prognostic variables.

The National Institute for Health and Care Excellence (NICE) recommended in the Head Injury Update Full Guideline (2007) (NICE. Clinical Guidelines CG56 Head Injury: Triage, Assessment, Investigation and Early Management of Head Injury in Infants, Children and Adults. London: NICE; 2007.) that research is needed to develop a consensus on criteria for lesions not currently considered to be surgically significant, namely TICH. This trial, Surgical Trial in Traumatic intraCerebral Haemorrhage [STITCH(TRAUMA)], was recommended by that NICE Head Injury Guideline Development Group.

**Objectives**

To determine whether or not a policy of Early Surgery in patients with TICH improved outcome compared with a policy of Initial Conservative Treatment.

To assess the relative costs and consequences of Early Surgery versus Initial Conservative Treatment.

To investigate the use of ICP monitoring for clinical management of head-injured patients with TICH and its effect on treatment decisions.

**Methods**

STITCH(TRAUMA) was an international, multicentre, pragmatic, randomised, parallel-group trial comparing early surgical evacuation of TICH with Initial Conservative Treatment. Only adult patients for whom the treating neurosurgeon was in equipoise about the benefits of early surgical evacuation compared with Initial Conservative Treatment were eligible for the trial. Patients had to be within 48 hours of head injury and to have no more than two TICHs larger than 10 ml. They were ineligible if they had a significant EDH or SDH that required surgery, if a haematoma was located in the cerebellum or if they had a severe pre-existing physical or mental disability or severe comorbidity that would lead to a poor outcome even if they made a full recovery from their head injury. An independent 24-hour telephone- and web-based randomisation service was used. Stratification by country was used together with minimisation by age and severity with a random component to ensure that the two groups were balanced. Patients were randomised to Early Surgery (within 12 hours) or to Initial Conservative Treatment. Delayed evacuation of the haematoma was permitted for patients in the Initial Conservative Treatment group if it became clinically appropriate. Outcome was measured at 6 months via a postal questionnaire using the Extended Glasgow Outcome Scale (GOSE).

Additional data were collected in those centres that practised invasive brain monitoring to see if there was evidence that such monitoring techniques would add value to clinical decision-making. Such monitoring was not mandatory.
The costing analysis was undertaken on the intention-to-treat basis from an international health services perspective. Resource-use requirements to deliver the interventions (e.g. staff time, overheads) and time spent on hospital wards were collected using site-specific questionnaires and case report forms. Hospital readmissions were reported on participant outcome questionnaires. Costing followed recommended procedures for international studies applying country-specific unit costs (sourced from site-specific questionnaires) to resource use data to generate total costs. Costs were transformed into 2013 international dollars.

Results

Between December 2009 and September 2012, 170 patients were recruited from 31 centres in 13 countries and randomly assigned to treatment groups: 83 to Early Surgery and 87 to Initial Conservative Treatment. The study was halted by the funding agency after the recruitment of 170 of the planned 840 patients because of low recruitment in the UK; only six patients had been recruited in the UK. The study was halted without the funding agency or the study team knowing the outcome despite the Data Monitoring Committee recommending that it should continue. This study reports results for 82 eligible patients assigned to Early Surgery and 86 eligible patients assigned to Initial Conservative Treatment.

The distribution of baseline variables between the two treatment groups was very similar. Patients ranged in age from 16 to 83 years with a median age of 50 years, and 122 (73%) were male. Prior to the head injury, 164 (98%) had a score on the Rankin Scale of 0 or 1, and 22 (13%) had a medical history of cardiovascular disease. The main causes of the head injury were road traffic accidents 113 (67%) and falls 47 (28%). Sixty-eight patients (40%) were admitted to another hospital prior to their transfer to the neurosurgical unit. At the time of randomisation, 70 (42%) patients had a Glasgow Coma Score (GCS) of 13–15, 78 (46%) a GCS of 8–12 and 20 (12%) a GCS of <8. The volume of the largest haematoma varied between 10 and 97 ml with a median of 23 ml, and 61 (36%) patients had a second haematoma between 0 and 26 ml with a median of 3 ml.

Of the 82 patients in the Early Surgery group, only 61 (74%) had surgery, 57 (93%) of these within 12 hours of randomisation. The reasons for not having surgery were patient or relative refusal (15) or change in medical status (6). Of the 86 patients randomised to Initial Conservative Treatment, 31 (36%) had surgery within 14 days of randomisation, 10 (32%) of these within 12 hours. The reasons for having surgery were neurological deterioration (29) or other (2).

Surgical patients in the Early Surgery group were more likely to have craniotomy than surgical patients in the Initial Conservative Treatment group (97% vs. 81%; Fisher’s exact test, $p = 0.016$). Surgical patients in the Early Surgery group had significantly higher pre-operative GCSs than those requiring surgery in the Initial Conservative Treatment group. Comparison of the baseline characteristics of patients in the Initial Conservative Treatment group who had surgery with those who did not showed that patients who deteriorated and went on to have surgery had larger haematomas initially (Mann–Whitney U-test, $p = 0.010$) and were more likely to have at least one pupil unreactive (Fisher’s exact test, $p = 0.0005$) but did not differ on age, GCS at the time of randomisation or presence of a second haematoma.

At some point in the first 2 weeks, seven (9%) Early Surgery patients were ICP monitored, compared with 16 (19%) Initial Conservative Treatment patients ($p = 0.073$), and this affected management decisions in one Early Surgery patient compared with 10 Initial Conservative Treatment patients ($p = 0.069$).
Six-month outcome was available for 82 Early Surgery patients and 85 Initial Conservative Treatment patients; one patient from the Initial Conservative Treatment group was lost to follow-up. Fifty-two (63%) Early Surgery patients had a favourable outcome on the dichotomised Glasgow Outcome Scale (GOS), compared with 45 (53%) Initial Conservative Treatment patients [odds ratio (OR) 0.65, 95% confidence interval (CI) 0.35 to 1.21; \( p = 0.171 \)], an absolute difference of 10.5% (95% CI −4.4% to 25.3%). Adjusting for age, volume and GCS gives an OR of 0.58 (95% CI 0.29 to 0.75; \( p = 0.122 \)). However, there was a highly significant difference in mortality at 6 months, with 12 (15%) Early Surgery patients dying, compared with 28 (33%) Initial Conservative Treatment patients (OR 0.35, 97% CI 0.16 to 0.75; \( p = 0.007 \)), and absolute difference of 18.3% (95% CI 5.7% to 30.9%). The Kaplan–Meier plot of survival for the two groups of patients illustrated the significant advantage of Early Surgery compared with Initial Conservative Treatment (\( p = 0.008 \)). The main causes of death were the initial head injury (Early Surgery 5 vs. Initial Conservative Treatment 14) and pneumonia (Early Surgery 4 vs. two Initial Conservative Treatment 2). This reduction in mortality was not associated with an increase in lower severe dependency and there were no vegetative survivors in either group.

For each of GOS, GOSE and Rankin Scale at 6 months there was a significant trend in improved outcomes in the Early Surgery group using the chi-squared trend analysis (\( p = 0.047 \), \( p = 0.052 \) and \( p = 0.043 \) respectively), although the proportional odds models did not reach statistical significance (OR 0.67, 95% CI 0.39 to 1.16, \( p = 0.153 \); OR 0.66, 95% CI 0.38 to 1.13, \( p = 0.127 \); OR 0.67, 95% CI 0.39 to 1.15, \( p = 0.147 \)). None of the pre-specified subgroups displayed any significant heterogeneity of treatment response, although patients with a GCS of 9–12 exhibited the best response to Early Surgery.

Considering outcome by allocated and received treatment, 33% (20 out of 61) of patients who were allocated to Early Surgery and had surgery died or were severely disabled at 6 months. However, 65% (20 out of 31) of patients who were allocated to Initial Conservative Treatment and had delayed surgery had died or were severely disabled at 6 months, compared with 37% (20 out of 54) of the conservatively treated patients who did not have surgery.

Patients randomised to the Early Surgery group had an average gain of 0.019 quality-adjusted life-years (QALYs) over a 6-month period (95% bootstrapped CI −0.004 to 0.043 QALYs), when compared with those randomised to the Initial Conservative Treatment. This is equivalent to an incremental QALY gain of 3.5 days over a 6-month period. The broad QALY gains are driven primarily by the increased chance of survival in the Early Surgery group.

**Conclusions**

The STITCH(TRAUMA) trial has demonstrated a large reduction in mortality associated with Early Surgery for parenchymal TICH (\( p = 0.007 \)) and there were no vegetative survivors. There was not a statistically significant effect on the pre-specified primary outcome in this reduced sample. However, the observed 10.5% advantage in favourable outcome for the Early Surgery group would have been statistically significant if it had been maintained for the trial sample size as originally planned. Nevertheless, this was a very strong signal that Early Surgery will indeed prevent deterioration. This is seen in the improvement in better outcomes in the ordinal analysis of the GOS and Rankin Scale. A larger trial is urgently needed to confirm or refute this finding.
Implications for health care

1. There is a strong case for operating on patients with TICH who have a GCS of 9–12. Those who are alert or just confused (GCS of 13–15) can probably be watched carefully for any deterioration because there is a safety margin which diminishes the lower down the GCS the patient descends. Once the GCS has dropped below 8, surgical intervention appears to be less effective.

2. Based on the results of the study, and the World Health Organization guidelines for cost-effectiveness, the Early Surgery intervention could be interpreted as offering a high probability of cost-effectiveness in both high- and upper middle-income countries. There may also be a high probability of cost-effectiveness in lower middle-income countries, but, based on the cost-effectiveness acceptability curve analysis, this conclusion would be more sensitive to the threshold value of cost-effectiveness imposed by decision-makers.

Recommendations for research

This trial has given a very strong signal that Early Surgery is superior to Initial Conservative Treatment for patients with TICH. This signal was evident despite the sample size being only 20% of that originally planned. Given that there are 800,000 such injuries each year in the world (8000 per year in the UK because the UK accounts for 1% of the world’s population of 7 billion), the 10.5% absolute improvement in favourable outcome represents 84,000 patients every year that could have a better outcome. If this is true, then the trial needs to be repeated with the utmost urgency to avoid this enormous annual excess death and disability rate that currently prevails for these patients.

Funding

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.
Criteria for inclusion in the *Health Technology Assessment* journal

Reports are published in *Health Technology Assessment* (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Health Technology Assessment* are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

**HTA programme**

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS.

‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

**This report**

The research reported in this issue of the journal was funded by the HTA programme as project number 07/37/16. The contractual start date was in September 2009. The draft report began editorial review in April 2014 and was accepted for publication in November 2014. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2015. This work was produced by Gregson *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Editor-in-Chief of Health Technology Assessment and NIHR Journals Library

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

Professor Aileen Clarke  Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick, UK

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Peter Davidson  Director of NETSCC, HTA, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Professor Elaine McColl  Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Health Sciences Research, Faculty of Education, University of Winchester, UK

Professor John Norrie  Health Services Research Unit, University of Aberdeen, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsmma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of members of the NIHR Journals Library Board:
www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: nihredit@southampton.ac.uk